Anavex Life Sciences Corp.AVXLNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank67
3Y CAGR-10.1%
5Y CAGR-0.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-10.1%/yr
vs +18.4%/yr prior
5Y CAGR
-0.7%/yr
Recent deceleration
Acceleration
-28.4pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$31.80M-15.4%
2025$37.59M-10.1%
2024$41.84M-4.3%
2023$43.72M+15.3%
2022$37.92M+15.0%
2021$32.98M+30.7%
2020$25.23M+13.3%
2019$22.26M+66.8%
2018$13.34M+25.0%
2017$10.67M-